Galapagos NV (NASDAQ:GLPG - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $24.15 and last traded at $24.34, with a volume of 159430 shares changing hands. The stock had previously closed at $25.65.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on GLPG shares. Royal Bank of Canada decreased their price objective on shares of Galapagos from $32.00 to $30.00 and set a "sector perform" rating for the company in a report on Friday, November 1st. TD Cowen lowered Galapagos from a "strong-buy" rating to a "strong sell" rating in a research report on Thursday. Finally, Kepler Capital Markets lowered shares of Galapagos from a "hold" rating to a "reduce" rating in a report on Wednesday, November 20th. Three investment analysts have rated the stock with a sell rating and six have issued a hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $30.75.
Get Our Latest Research Report on Galapagos
Galapagos Price Performance
The stock has a 50 day moving average of $27.23 and a 200 day moving average of $27.53.
Institutional Trading of Galapagos
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Creative Planning acquired a new position in shares of Galapagos during the second quarter worth $456,000. GAMMA Investing LLC grew its position in shares of Galapagos by 77.4% in the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after buying an additional 974 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of Galapagos in the third quarter valued at about $1,077,000. Signaturefd LLC lifted its stake in shares of Galapagos by 65.6% in the third quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company's stock worth $185,000 after acquiring an additional 2,541 shares during the period. Finally, Headlands Technologies LLC boosted its holdings in Galapagos by 56.7% in the second quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company's stock valued at $31,000 after acquiring an additional 446 shares during the last quarter. Institutional investors own 32.46% of the company's stock.
About Galapagos
(
Get Free Report)
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Featured Articles
Before you consider Galapagos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.
While Galapagos currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
